+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021

  • ID: 5367447
  • Report
  • June 2021
  • Region: United States
  • 210 pages
  • Aruvian Research

FEATURED COMPANIES

  • AbbVie
  • Apotex
  • Bristol Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Novartis
  • MORE
With the COVID-19 having made a severe impact on various industries in the United States, it is challenging to predict precisely how the pharmaceutical and healthcare market will be performing in a short time. However, there is no doubt that the pharmaceutical and healthcare sector has been affected seriously. With the economic slowdown setting in due to the pandemic, the US pharmaceutical and healthcare industry is expected to decelerate in the short term.

The US pharmaceutical industry is a highly globalized industry dominated by multinational companies that engage in significant business activity in many countries and whose products are distributed and marketed worldwide. Over the past few decades, the industry has undergone dramatic structural changes, with the rise of the biotechnology sector, substantial growth in demand driven by demographics and substitution away from other therapeutic modalities such as surgery, and increased competition from globally active generic manufacturers.

The publisher presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of United States in its research report Pharmaceutical and Healthcare Industry in the US - Forecast and Analysis 2021.

The report covers the following data:
  • An in-depth coverage of the pharmaceutical and healthcare industry in the US by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for clinical trials in the US.
  • A SWOT analysis of the US pharmaceutical and healthcare industry.
  • A Porter's Five Forces Strategic Analysis of the US pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
  • We take an up-close view of the regulatory framework governing the US pharmaceutical and healthcare industry.
  • Competition in the industry, along with an in-depth analysis of the major players like AstraZeneca, Eli Lilly, Glaxo Smith Kline, and many others are included.
A detailed forecast of the US pharmaceutical and healthcare industry by segments completes this comprehensive analysis.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie
  • Apotex
  • Bristol Myers Squibb
  • Gilead Sciences
  • Johnson & Johnson
  • Novartis
  • MORE
A. Executive Summary

B. Industry Definition

C. Pharmaceutical & Healthcare Industry in the US
C.1 Impact of COVID-19 on the Industry
C.2 Pharmaceutical Sector Analysis
C.3 Healthcare Sector Analysis
C.4 Market for Prescription Drugs
C.5 Market for Patented Drugs
C.6 Market for OTC Medicines
C.7 Market for Generic Drugs
C.8 Clinical Trials in the US

D. US Pharmaceutical & Healthcare Industry: SWOT Analysis
D.1 Strengths to Build Upon
D.2 Weaknesses to Overcome
D.3 Opportunities to Exploit
D.4 Threats to Overcome

E. US Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
E.1 Bargaining Power of Buyers
E.2 Bargaining Power of Suppliers
E.3 Competitive Rivalry in the Industry
E.4 Threat of New Entrants
E.5 Threat of Substitutes

F. Chronic Medical Conditions in the US
F.1 Overview
F.2 Alzheimer’s Disease
F.3 Arthritis
F.4 Cancer
F.5 Cardiovascular Disease
F.6 Diabetes
F.7 Obesity

G. Regulatory Framework of the Industry
G.1 Overview
G.2 Regulations for New Drugs
G.3 The American Health Care Act
G.4 Other Regulations
G.4.1 Prescription Drug User Fee Act
G.4.2 Regulations governing Generic Drugs
G.4.3 Bolar Amendment
G.4.4 Regulations governing Biosimilars
G.4.5 Regulations governing OTC Medicines
G.4.6 Tax Reform Bill
G.4.7 Pricing and Reimbursement Regime
G.4.8 Proposition 61 - The California Drug Price Relief Act
G.4.9 Senate Bill No. 17
G.4.10 Regulations governing Promotion of Pharmaceuticals
G.4.11 What does the Payer Landscape look like?
G.5 Challenges with Intellectual Property Rights

H. Import/Export of Pharmaceuticals

I. Competition in the Industry
I.1 Competitive Landscape
I.2 Impact of COVID-19 on Competition
I.3 Impacts on Competition
I.4 Competition in the Generic Drugs Sector
I.5 Competition in the US Pharmacy Sector
I.6 Competition in the US Drug Distribution Market

J. Forecast: Pharmaceutical & Healthcare Industry in the US
J.1 Outlook of the US Pharmaceutical Industry
J.2 Outlook of the US Healthcare Industry
J.3 Outlook for Prescription Drugs Sector
J.4 Outlook for Patented Drugs Market
J.5 Outlook for OTC Medicine Market
J.6 Outlook for the Generic Drugs Market

K. Pharmaceutical & Healthcare Industry: Major Players
K.1 AbbVie
K.1.1 Corporate Analysis
K.1.2 Business Segment Analysis
K.1.3 Financial Analysis
K.1.4 SWOT Analysis
K.2 Amgen
K.2.1 Corporate Analysis
K.2.2 Business Segment Analysis
K.2.3 Financial Analysis
K.2.4 SWOT Analysis
K.3 Apotex
K.3.1 Corporate Analysis
K.3.2 Business Segment Analysis
K.3.3 Financial Analysis
K.3.4 SWOT Analysis
K.4 AstraZeneca
K.4.1 Corporate Analysis
K.4.2 Business Segment Analysis
K.4.3 Financial Analysis
K.4.4 SWOT Analysis
K.5 Bristol Myers Squibb
K.5.1 Corporate Analysis
K.5.2 Business Segment Analysis
K.5.3 Financial Analysis
K.5.4 SWOT Analysis
K.6 Eli Lilly and Company
K.6.1 Corporate Analysis
K.6.2 Business Segment Analysis
K.6.3 Financial Analysis
K.6.4 SWOT Analysis
K.7 Gilead Sciences
K.7.1 Corporate Analysis
K.7.2 Business Segment Analysis
K.7.3 Financial Analysis
K.7.4 SWOT Analysis
K.8 GlaxoSmithKline
K.8.1 Corporate Analysis
K.8.2 Business Segment Analysis
K.8.3 Financial Analysis
K.8.4 SWOT Analysis
K.9 Johnson & Johnson
K.9.1 Corporate Analysis
K.9.2 Business Segment Analysis
K.9.3 Financial Analysis
K.9.4 SWOT Analysis
K.10 Merck & Co.
K.10.1 Corporate Analysis
K.10.2 Business Segment Analysis
K.10.3 Financial Analysis
K.10.4 SWOT Analysis
K.11 Novartis
K.11.1 Corporate Analysis
K.11.2 Business Segment Analysis
K.11.3 Financial Analysis
K.11.4 SWOT Analysis
K.12 Pfizer
K.12.1 Corporate Analysis
K.12.2 Business Segment Analysis
K.12.3 Financial Analysis
K.12.4 SWOT Analysis
K.13 Sanofi SA
K.13.1 Corporate Analysis
K.13.2 Business Segment Analysis
K.13.3 Financial Analysis
K.13.4 SWOT Analysis
K.14 Teva Pharmaceutical Industries Ltd.
K.14.1 Corporate Analysis
K.14.2 Business Segment Analysis
K.14.3 Financial Analysis
K.14.4 SWOT Analysis

L. Glossary of Terms

M. Research Methodology

N. Disclaimer

List of Figures
Figure 1: Growth of the Pharmaceutical Sales in the US, 2016-2030
Figure 2: Clinical Trial Registrations in the US, 2016-2019
Figure 3: Porter's Five Forces Analysis of the US Pharmaceutical Industry
Figure 4: Bargaining Power of Buyers in the US Pharmaceutical Industry
Figure 5: Bargaining Power of Suppliers in the US Pharmaceutical Industry
Figure 6: Competitive Rivalry in the US Pharmaceutical Industry
Figure 7: Threat of New Entrants to the US Pharmaceutical Industry
Figure 8: Threat of Substitutes to the US Pharmaceutical Industry
Figure 9: Import-Export of Pharmaceuticals in the US (in USD Million), 2016-2025
Figure 10: Expenditure on Healthcare in the US, 2016-2030
Figure 11: Forecast of the Prescription Drug Market in the US, 2016-2030
Figure 12: Forecast of the Patented Drugs Sector in the US, 2016-2030
Figure 13: Forecast of the OTC Medicine Market, 2016-2030
Figure 14: Forecast of the Generic Drug Market in the US, 2017-2025

List of Tables
Table 1: Growth of the Pharmaceutical Sales in the US, 2016-2030
Table 2: Healthcare Resources in the US, 2015-2020
Table 3: Inpatient/Outpatient Statistics in the US, 2015-2020
Table 4: Major Features of the Affordable Care Act
Table 5: Import-Export of Pharmaceuticals in the US (in USD Million), 2016-2025
Table 6: Market Share of Leading Players in the US Pharmaceutical Industry (%), 2020
Table 8: Statistics of the US Pharmaceutical & Healthcare Industry in the US, 2019-2025
Table 9: Expenditure on Healthcare in the US, 2016-2030
Table 10: Government Expenditure on Healthcare in the US, 2017-2025
Table 11: Healthcare Expenditure by Private Sector on Healthcare in the US, 2017-2025
Table 12: Forecast of the Prescription Drug Market in the US, 2016-2030
Table 13: Forecast of the Patented Drugs Sector in the US, 2016-2030
Table 14: Forecast of the OTC Medicine Market, 2016-2030
Table 15: Forecast of the Generic Drug Market in the US, 2017-2025
Note: Product cover images may vary from those shown
  • AbbVie
  • Amgen
  • Apotex
  • AstraZeneca
  • Bristol Myers Squibb
  • Eli Lilly and Company
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Novartis
  • Pfizer
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
Note: Product cover images may vary from those shown
Adroll
adroll